Recent News

• 03.31.2026 - NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
• 03.25.2026 - NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
• 03.12.2026 - NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
• 03.10.2026 - NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
• 02.10.2026 - NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
• 12.16.2025 - NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
• 12.11.2025 - NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

Recent Filings

• 03.31.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.12.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.10.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 8-K Current report
• 02.11.2026 - 8-K Current report
• 02.11.2026 - EX-99.1 EX-99.1
• 02.10.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.30.2026 - 8-K Current report
• 01.07.2026 - 8-K Current report
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities